Barry S. Coller

The Rockefeller University

Primary Section: 41, Medical Genetics, Hematology, and Oncology
Secondary Section: 42, Medical Physiology and Metabolism
Membership Type:
Member (elected 2003)

Research Interests

Blood platelets help to arrest bleeding at sites of vascular injury by adhering to damaged blood vessels, aggregating one with another, and facilitating thrombin generation and fibrin clot formation. Platelet abnormalities, therefore, result in excessive bleeding. Platelets also contribute to thrombotic vascular disease since platelet aggregation can close off a blood vessel that is narrowed by atherosclerosis, resulting in a myocardial infarction or stroke. By studying human genetic disorders of platelet surface receptors, I and others identified the GPIIb/IIIa (IIb 3) integrin receptor as important in platelet aggregation. I then produced monoclonal antibodies that block the binding of ligands to the receptor, and thus prevent platelet aggregation. I helped to develop one of these antibodies into a drug (abciximab; Centocor) that prevents thrombotic complications of coronary angioplasty and stent placement. It is now being evaluated as treatment for stroke. Recently, I began collaborative studies to understand better the vascular complications of sickle cell disease, including stroke and episodes of severe bone pain. We have identified the V 3 integrin receptor and adherent leukocytes as important in producing blood vessel obstruction by sickle cells. We are now testing new therapeutic interventions to inhibit the interactions between leukocytes, sickle red blood cells, and the blood vessel wall.

Powered by Blackbaud
nonprofit software